![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DJ Greenblatt, M Divoll, JS Harmatz and RI Shader
Thirty-eight healthy male and female volunteers, 22 to 84 years of age, ingested single 30-mg doses of oxazepam tablets in the fasting state. Oxazepam plasma concentrations were determined by electron-capture gas- liquid chromatography in multiple samples drawn during 48 hr after the dose. Absorption of oxazepam was relatively slow with peak plasma levels reached an average of 2 to 3 hr after dosage. First-order absorption was observed in only 22 of the 38 subjects. Elimination half- life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr). Half-life was not associated with age in males but tended to increase with age in females (r = 0.45). Oxazepam was extensively bound to plasma protein. The mean free fraction was 4.3% and did not differ between sexes. Free fraction tended to increase with age (r = 0.25), in part because of significantly lower plasma albumin concentrations in the elderly (r = - 0.58). Assuming 100% systemic availability, clearance of total as well as unbound oxazepam was significantly greater in men than in women. Intrinsic clearance tended to decline with age in men (r = -0.21) and women (r = -0.24) but these associations were not significant. Higher oxazepam clearance was associated with heavy cigarette smoking but this did not explain the sex-related difference. Thus, sex is a more important determinant of oxazepam clearance than is age.
This article has been cited by other articles:
|
|
 |
|
  T. Sakuma, W. Bhadhprasit, T. Hashita, and N. Nemoto Synergism of Glucocorticoid Hormone with Growth Hormone for Female-Specific Mouse Cyp3a44 Gene Expression Drug Metab. Dispos., May 1, 2008; 36(5): 878 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Court, Q. Hao, S. Krishnaswamy, T. Bekaii-Saab, A. Al-Rohaimi, L. L. von Moltke, and D. J. Greenblatt UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 656 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Court, S. X. Duan, C. Guillemette, K. Journault, S. Krishnaswamy, L. L. von Moltke, and D. J. Greenblatt Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9 Drug Metab. Dispos., November 1, 2002; 30(11): 1257 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ericsson, B. Tholander, J. A. Björkman, M. Nordlander, and C. G. Regårdh Pharmacokinetics of New Calcium Channel Antagonist Clevidipine in the Rat, Rabbit, and Dog and Pharmacokinetic/Pharmacodynamic Relationship in Anesthetized Dogs Drug Metab. Dispos., May 1, 1999; 27(5): 558 - 564. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
